Ursosan (Ursodeoxycholic acid) 250 mg

Instructions for Ursosan (Ursodeoxycholic acid) 250 mg

Release Form Ursodeoxycholic acid
cap. 250 mg: 10, 50 or 100
Tab, 500 mg captive membrane: 10, 50 or 100

Description Ursodeoxycholic acid:

Pills covered with a film shell of white or almost white, elongated, double-bumped, on one side and deep dividing risk on the other; On the fracture - white or almost white.

1 tab.
ursodeosoxicholic acid 500 mg
Auxiliary substances: starch maize - 94.5 mg, starch maize pre-gelatinized - 48 mg, carboxymethylstarchmal sodium (type A) - 13 mg, silicon dioxidal Loid - 15 mg, magnesium stearat - 14.5 mg.

Shell composition:
Opadra white 03B28796 - 5 mg (Hypermellosa 6 - 3.13 mg, titanium dioxide - 1.56 mg, macro-goal 400 - 0.31 mg).

10 - Packages of cell outline (1) - packs of cardboard.
10 - Packages of cell outline (5) - packs of cardboard.
10 - Packages of cell outline (10) - packs of cardboard.

ATX codes
A05AA02 Ursodeoxycholic acid

Pharmaceutical / Group Membership Ursosan
Hepatotrektor with gastric and cholelitolithic action

Valid substance
ursodeosoxicholic acid

Pharmaceutical group
Hepathoprotector

Retention Conditions Ursodeoxycholic acid
Pills should be kept in a light-protected place at temperatures between 15° and 25°C.

Best before date Ursosan
The expiration date is four years.

The capsules should be kept in a dry, light-protected place at temperatures between 15° and 25°C.
Do not apply after expiration of expiration date.
The drug should be kept in a place that is not accessible to children.

Indications Ursosan:

• uncomplicated gastric-stone disease: billiar sweetness; Dissolution of cholesterol gallstones with a functioning
• gallbladder; 
• Prevention of relapses of stone formation after cholecystectomy;
• Chronic hepatitis of various genes (including toxic, 
• medicinal);
• Cholestatic liver diseases of various genes, 
• including primary bilinary cirrhosis (in the absence of any indication of
• decompensation), primary scleroding cholangitis, 
• cystic fibrosis (mucovissido) h);
• Non-alcohol fatty liver disease, 
• including non-alcohol steatohepatitis;
• Alcoholic liver disease;
• chronic viral hepatitis;
• Diskinesia of the bile pathways
• billiar reflux-gastrit and reflux-esophagitis.

Method of application, course and dosage Ursosan:

They take in, during or after meals, without chewing, drinking enough water.
To ensure the recommended dose, the tablet should be divided in half by breaking the risk. Segments broken incorrectly should not be used. When you hold a segment in the mouth, you feel bitter taste.

For the solution of cholesterol gallstones, the average daily dose of the drug is ten mg/kg (up to twelve to 15 mg/kg). The daily dose of the drug is taken once per night. The treatment course is six to twelve months or more until the stones are completely dissolved. If gallbladder stones do not decrease after twelve months of treatment, the drug should be abolished.

liver function violation Ursosan
Displayed when the liver is insufficient.

Implementation Conditions Ursodeoxycholic acid
The drug is released by prescription.

• Nosology Ursodeoxycholic acid (ICD codes)
• B15
• Acute hepatitis A
• B16
• Acute hepatitis B
• B17.1
• Acute hepatitis C
• B18.1
• Chronic viral hepatitis B without a delta agent
• B18.2
• Chronic viral hepatitis C
• E84
• Painted fibrosis
• K21.0
• Gastroesophagel reflux with esophagite
• K30
• Functional Dispatch (digestive disorder)
• K70
• Alcoholic liver disease
• K71
• Toxic liver loss
• K74
• Fibrosis and cirrhosis of the liver
• K80
• Gemstone disease [cholelitias] (including liver colic)
• K82.8
• Other refined gallbladder and bladder diseases (including diskinesia)
• K83.0
• Holangite
• Z29.8
• Other refined preventive measures

Pharmacological effect Ursodeoxycholic acid:

Hepatoprotective drug. It also has cholelytic, hypolipidemic, hypocholesterolemic and immunomodulatory effects. Possessing high polar properties, ursodeoxycholic acid (UDHC) is incorporated into the hepatocyte, cholangiocyte and GI-CT epitheliocyte membrane, stabilizes its structure and protects the cell from the damaging effect of toxic bile acid salts, thereby reducing the cytotoxic effect thereof. It forms non-toxic mixed mycelles with lipophilic (toxic) bile acids, which reduces the ability of gastric reflux to damage cell membranes in cholestatic liver disease, biliary reflux gastritis, and reflux esophagitis.